Sabin Vaccine Institute Receives $35 Million from BARDA with Potential of up to $214 Million for Ebola Sudan and Marburg Vaccines Read more
Ono Enters an Option and Research Collaboration Agreement with Monash University to Discover Anti-GPCR Antibodies in the Autoimmune and Inflammatory Diseases Read more
FDA Approves Luye Pharma’s Rykindo for the Treatment of Schizophrenia and Bipolar 1 Disorder Read more
Daiichi Sankyo Submits Application for Marketing Approval of mRNA COVID-19 Vaccine (DS-5670) in Japan Read more
Takeda’s EXKIVITY (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC Read more
Enhertu Approved by Health Canada as the First HER2-Directed Therapy for Patients with HER2-Low Metastatic Breast Cancer Read more
Catalent and Ethicann Sign Development and License Agreement for New Fast-Dissolve Cannabinoid-Based Treatments Read more